AstraZeneca Partners with Alteogen for Subcutaneous Cancer Therapies

AstraZeneca and Alteogen Inc. have signed an exclusive license agreement for ALT-B4, a next-generation hyaluronidase enzyme based on Alteogen’s Hybrozyme™ technology. This collaboration grants AstraZeneca worldwide rights to use ALT-B4 for developing subcutaneous formulations of multiple oncology drugs, aiming to enhance patient convenience and streamline cancer treatment. Unlike intravenous infusions, subcutaneous delivery offers shorter administration times, reducing the burden on patients, healthcare providers, and medical facilities. Alteogen will oversee the clinical and commercial supply of ALT-B4, ensuring a steady pipeline for AstraZeneca’s oncology portfolio.

AstraZeneca’s Chief Medical Officer, Cristian Massacesi, emphasized the company’s commitment to innovating cancer treatment delivery, while Alteogen’s CEO, Dr. Soon Jae Park, highlighted the significance of expanding Hybrozyme™ technology in the global oncology space. The agreement includes an upfront payment, milestone-based financial incentives, and royalties on future sales. This partnership marks a significant step toward making advanced cancer therapies more accessible and efficient for patients worldwide.